Meeting News

Tumor mutational burden does not predict efficacy of pembrolizumab, chemotherapy for advanced NSCLC

September 9, 2019
BARCELONA —
Meeting News

First-line durvalumab plus chemotherapy improves OS in extensive-stage small cell lung cancer

September 9, 2019
BARCELONA — The addition of durvalumab to platinum-etoposide chemotherapy significantly extended OS among patients with
Meeting News

Researchers identify mutations associated with treatment sensitivity, resistance in NSCLC

September 8, 2019
BARCELONA —STK11 and KEAP1 mutations appeared associated with poorer outcomes among patients with
Meeting NewsPerspective

Ipilimumab-nivolumab combination safe for historically unstudied patients with lung cancer

September 8, 2019
BARCELONA — The combination of
Meeting NewsPerspective

Novel KRAS inhibitor induces disease control in 96% of treated patients with non-small cell lung cancer

September 8, 2019
BARCELONA — AMG 510 appeared well-tolerated and showed promising antitumor activity among patients with locally advanced or metastatic…
Meeting News

IASLC: All physicians should screen patients with cancer for tobacco use

September 7, 2019
BARCELONA — The International Association for the Study of Lung Cancer, or IASLC, today issued a declaration at its World Conference on Lung…

International Association for the Study of Lung Cancer announces president-elect, board members

August 31, 2019
Heather A. Wakelee, MD, has been chosen president-elect of International Association for the Study of Lung Cancer. Wakelee, professor of…
Meeting NewsPerspective

Pembrolizumab plus chemotherapy prolongs OS, PFS for metastatic lung cancer

October 1, 2018
The addition of pembrolizumab to chemotherapy extended OS and PFS compared with chemotherapy alone among patients with metastatic, squamous…
Meeting News

Women with lung cancer live longer than men

October 1, 2018
Women with newly diagnosed stage I to stage III non-small cell lung cancer appeared to have longer OS than their male counterparts, according to…
Meeting NewsPerspective

Durvalumab extends OS in advanced lung cancer

September 28, 2018
Durvalumab prolonged OS among patients with locally advanced, unresectable stage III non-small cell lung cancer that did not progress following…